Matching articles for "Kimyrsa"

In Brief: Oritavancin (Kimyrsa) for Skin and Skin Structure Infections (online only)

   
The Medical Letter on Drugs and Therapeutics • August 23, 2021;  (Issue 1631)
The FDA has approved Kimyrsa (Melinta), a new IV formulation of the long-acting lipoglycopeptide antibiotic oritavancin, for treatment of adults with acute bacterial skin and skin structure infections caused...
The FDA has approved Kimyrsa (Melinta), a new IV formulation of the long-acting lipoglycopeptide antibiotic oritavancin, for treatment of adults with acute bacterial skin and skin structure infections caused by susceptible gram-positive bacteria. Orbactiv (Melinta), another IV formulation of oritavancin, was approved in 2014 for the same indication. Kimyrsa has a smaller infusion volume (250 mL vs 1 L) and a shorter infusion time (1 hour vs 3 hours) compared to Orbactiv (see Table 1).
Med Lett Drugs Ther. 2021 Aug 23;63(1631):e1-2 | Show Full IntroductionHide Full Introduction